Knight Therapeutics (KHTRF) announced that its Mexican affiliate, Grupo Biotoscana de Especialidad, has submitted a marketing authorization application for CREXONT to COFEPRIS, the Mexican health regulatory agency, for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults. CREXONT is a novel, oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson’s disease. In January 2024, Knight announced that it had entered into an agreement with Amneal Pharmaceuticals (AMRX) for the exclusive rights to seek regulatory approval and commercialize CREXONT in Canada and Latin America. In July 2025, Knight announced that CREXONT submission was accepted for review by Health Canada.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
- Knight Therapeutics closes acquisition of Paladin
- Knight Therapeutics Secures US$50 Million Credit Facility to Fuel Growth
- Knight Therapeutics closes $50M revolving credit facility
- Knight Therapeutics Secures Strategic Licensing Agreement with Sumitomo Pharma America, Boosting Market Potential and Investment Appeal